The FDA Pharmacy Compounding Advisory Committee meets July 23, 2026 to vote on the regulatory status of four widely tracked peptides. Background, what the committee actually decides, three possible outcomes, and what your tracking should look like in the meantime.
A 90-Day Countdown to a Vote That Affects Hundreds of Thousands of Tracked Protocols On July 23, 2026, the FDA's **Pharmacy Compounding Advisory Committee (PCAC)** is scheduled to vote on the bulk-drug-substance status of four peptides that, taken together, represent the bulk of the recovery and immune-modulation peptide research happening in the United States: **BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV, and MOTS-c**. The vote happens against the backdrop of one of the most volatile regulatory cycles for compounded peptides in two decades. The 2023 FDA Category 2 designation pushed these compounds out of legitimate compounding-pharmacy supply chains. The February 27, 2026 announcement by HHS Secretary Robert F. Kennedy Jr. signaled that approximately 14 of those 19 peptides would move back to Category 1. The July 23 PCAC vote is the formal mechanism that turns the announcement into rule. If you're a tracker — running a protocol, logging doses, watching biomarkers across draws — this vote determines whether your sourcing pathway changes in 90 days, what your provider can prescribe, and what the regulatory status looks like on every page that covers these compounds. Here's what's actually on the table, what the four peptides do, and how to think about your tracking in the meantime. This post is educational reporting on regulatory developments. MyProtocolStack does not provide medical advice. Any protocol decision is a conversation with your licensed healthcare provider.
The compounding-pharmacy regulatory framework runs on a two-list system. Category 1 substances are eligible for use in compounded preparations under FDA oversight. Category 2 substances are flagged with concerns that preclude routine compounding use. The list is governed by section 503A of the Federal Food, Drug, and Cosmetic Act and reviewed by PCAC, an independent advisory committee.
In late 2023, the FDA moved 19 widely used peptides from Category 1 to Category 2. The agency cited insufficient safety data, not specific adverse event signals, as the rationale. The practical effect was immediate: licensed 503A and 503B compounding pharmacies could no longer legally prepare these peptides for patients. Physicians who had been prescribing them through legitimate channels lost access overnight, and a gray market for research-chemical sourcing expanded to fill the gap.
In February 2026, HHS Secretary RFK Jr. publicly stated that the original Category 2 placement was procedurally flawed — applied without the specific safety signal the statute requires — and that approximately 14 of the 19 restricted peptides would be returned to Category 1. The July 23, 2026 PCAC meeting is the regulatory body that formally votes on the four peptides at the center of the highest-volume tracking activity: BPC-157, TB-500, KPV, and MOTS-c.
PCAC votes are advisory; the FDA Commissioner makes the final regulatory decision. But PCAC recommendations are followed in the overwhelming majority of cases.
### [BPC-157](/peptides/bpc-157)
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It is the most-researched compound in the recovery-peptide category, with preclinical literature covering tendon and ligament repair, gut-mucosa integrity, and angiogenesis (new blood vessel formation).
Trackers running BPC-157 commonly log [hs-CRP](/biomarkers/hs-crp), [ferritin](/biomarkers/ferritin), and CBC with differential to monitor the inflammation arc during a recovery cycle. The compound is the anchor in the [Wolverine Recovery Stack](/stacks/wolverine-recovery), the most-researched soft-tissue repair combination in the community.
If PCAC votes to return BPC-157 to Category 1, licensed compounding pharmacies regain the ability to prepare it under physician prescription. If the vote upholds Category 2, the gray-market sourcing pattern continues.
### [TB-500](/peptides/tb-500)
TB-500 is a synthetic 17-amino-acid fragment of the larger Thymosin Beta-4 peptide. Where BPC-157 acts locally, TB-500 drives systemic actin remodeling and cell migration — which is why the two are commonly stacked rather than substituted. TB-500's ~2-day half-life supports a twice-weekly dosing pattern, contrasted with BPC-157's daily cadence.
Trackers running TB-500 alongside BPC-157 in the Wolverine Stack typically watch the same inflammation panel — [hs-CRP](/biomarkers/hs-crp), [ferritin](/biomarkers/ferritin), [WBC](/biomarkers/wbc) — across the cycle. The compound also appears in the broader [Injury Rehabilitation Stack](/stacks/injury-rehab) referenced in post-surgical and chronic-tendinopathy research.
### [KPV](/peptides/kpv)
KPV is the C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte-stimulating hormone). Its research base is narrower than BPC-157 or TB-500 but specific: documented anti-inflammatory activity at the gut mucosa, which is why it appears in the [Immune Resilience Stack](/stacks/immune-resilience) alongside Thymosin Alpha-1 and LL-37.
Trackers researching KPV typically pair it with inflammation markers ([hs-CRP](/biomarkers/hs-crp), [IL-6](/biomarkers/il-6)) and immune-cell counts ([WBC](/biomarkers/wbc), [platelets](/biomarkers/platelets)). The compound's regulatory status has been a quieter conversation than BPC-157's because the volume of users tracking it is smaller — but the July 23 vote covers it directly.
### [MOTS-c](/peptides/mots-c)
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded in mitochondrial DNA. Its mechanism is distinct from the other three on the docket — it acts on mitochondrial signaling and metabolic homeostasis rather than tissue repair. The published research base is smaller and earlier-stage, but it is referenced in the metabolic-tracking community for insulin-sensitivity and exercise-capacity research.
Trackers running MOTS-c commonly watch metabolic markers — [fasting insulin](/biomarkers/fasting-insulin), [HbA1c](/biomarkers/hba1c), [fasting glucose](/biomarkers/fasting-glucose) — across cycles. Like the other three on the July 23 docket, the compound's path to legal compounding-pharmacy supply runs directly through this PCAC vote.
The committee votes on a narrow regulatory question: should the bulk drug substance be eligible for use in compounded preparations under section 503A? The vote considers four factors:
1. The physical and chemical characterization of the substance
2. Available safety data
3. Available evidence of effectiveness
4. Historical use in compounding
PCAC does not vote on whether the compound should be available over the counter. It does not vote on dosing recommendations. It does not vote on whether the compound is "approved" for any specific use. The vote is exclusively about whether 503A pharmacies can legally compound and dispense the substance under physician prescription.
That distinction matters for trackers. A favorable vote does not create a new "approved" indication. It restores the physician-prescription pathway that existed before late 2023.
### Outcome 1: Return to Category 1 (most expected, given the February announcement)
PCAC votes to recommend Category 1 status for all four compounds. The FDA Commissioner accepts the recommendation. 503A pharmacies resume legal compounding. Physicians regain prescriptive authority through legitimate pharmaceutical channels. Trackers who had moved to gray-market sourcing during the 2023–2026 window can transition to compounding-pharmacy sourcing under provider supervision.
### Outcome 2: Partial reclassification (possible)
PCAC votes Category 1 for some but not all of the four. BPC-157 and TB-500 — with the longer research history — return; KPV and MOTS-c — with smaller evidence bases — stay in Category 2 pending more data. This is the most procedurally cautious path PCAC can take and matches the agency's general preference for incremental movement.
### Outcome 3: Status quo (lowest probability, but non-zero)
PCAC votes to retain Category 2 for all four. The February announcement does not translate into formal regulatory change. The gray market sourcing pattern continues unchanged. This outcome is unlikely given the political momentum behind the reclassification but is not eliminated until the vote happens.
Whatever the July 23 outcome, the tracking practice doesn't change. Three principles for the 90-day window:
Baseline first. If you're already running any of the four compounds, get a baseline lab panel now. The Wolverine Recovery and Immune Resilience stacks have specific [biomarker recommendations](/stacks/wolverine-recovery) — log them at draw, set the next draw at 6 weeks, and chart the trend. Sourcing volatility is a risk; tracking discipline is a hedge.
Document the source. Whatever your sourcing pathway, document it (vial label, batch number, vendor, reconstitution date). Post-vote, if the regulatory status changes, you'll want a clear record of what you were running. The [Reconstitution Calculator](/calculators/bpc-157) handles the math; your protocol log handles the record.
Have the provider conversation. A favorable PCAC vote restores physician-prescription compounding-pharmacy access. Trackers who have been operating in the gray market should plan now for the conversation with their provider about transitioning to a legitimate prescription pathway if the vote breaks favorably. The transition is easier with documented baseline labs and a tracked protocol than without.
The July 23 vote is one regulatory data point in a much longer arc. The discipline that survives any regulatory cycle is consistent tracking, baseline labs, and provider-supervised decisions. We'll cover the vote outcome and what it means in detail when it lands.
---
Track your protocol against your bloodwork. MyProtocolStack lets you log every dose, upload your lab PDFs, and chart the biomarkers on this page across every draw. StackAI reads your panel in context of what you're actually running. [Start tracking — free →](/auth/login)
*Educational reporting on regulatory developments. Not medical advice. Compounds discussed are not FDA-approved unless specifically noted. Any protocol decision requires a licensed healthcare provider.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →